Eliem Therapeutics (NASDAQ:ELYM) Trading 0.5% Higher

Eliem Therapeutics, Inc. (NASDAQ:ELYM) shares rose 0.5% during mid-day trading on Monday . The stock traded as high as $4.12 and last traded at $3.87. Approximately 95,362 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 583,013 shares. The stock had previously closed at $3.85.

Eliem Therapeutics Trading Up 0.5 %

The company has a market capitalization of $107.28 million, a price-to-earnings ratio of -2.63 and a beta of 0.51. The firm’s 50 day simple moving average is $2.98 and its 200-day simple moving average is $2.77.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Eliem Therapeutics stock. Cerity Partners LLC acquired a new position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 13,821 shares of the company’s stock, valued at approximately $37,000. Cerity Partners LLC owned approximately 0.05% of Eliem Therapeutics at the end of the most recent quarter. 69.76% of the stock is owned by institutional investors and hedge funds.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.